Teva Pharmaceutical Industries Limited

Tel Aviv Stock Exchange TEVA.TA

Teva Pharmaceutical Industries Limited Price to Book Ratio (P/B) on January 14, 2025: 3.13

Teva Pharmaceutical Industries Limited Price to Book Ratio (P/B) is 3.13 on January 14, 2025, a 87.28% change year over year. Price to book ratio compares the stock price to the book value per share; above 1 indicates market values company more than its book value.
  • Teva Pharmaceutical Industries Limited 52-week high Price to Book Ratio (P/B) is 11.80 on December 20, 2024, which is 277.01% above the current Price to Book Ratio (P/B).
  • Teva Pharmaceutical Industries Limited 52-week low Price to Book Ratio (P/B) is 1.63 on January 17, 2024, which is -47.98% below the current Price to Book Ratio (P/B).
  • Teva Pharmaceutical Industries Limited average Price to Book Ratio (P/B) for the last 52 weeks is 2.53.
Key data
Date Price to Book Ratio (P/B) Dividend Yield Free Cash Flow Yield Price to Earnings Ratio (P/E)
Market news
Loading...
Tel Aviv Stock Exchange: TEVA.TA

Teva Pharmaceutical Industries Limited

CEO Mr. Richard D. Francis
IPO Date Aug. 12, 2002
Location Israel
Headquarters 124 Dvora Hanevi’a Street
Employees 37,000
Sector Health Care
Industries
Description

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.

Similar companies

LUMI.TA

Bank Leumi Le-Israel B.M.

USD 12.30

0.72%

ELAL.TA

El Al Israel Airlines Ltd.

USD 2.56

-3.58%

BEZQ.TA

Bezeq The Israel Telecommunication Corp. Ltd

USD 1.56

3.32%

TSEM.TA

Tower Semiconductor Ltd.

USD 50.62

-2.66%

ESLT.TA

Elbit Systems Ltd.

USD 292.23

-0.16%

StockViz Staff

January 15, 2025

Any question? Send us an email